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Mutations in genes encoding components of iron homeostasis 
mechanisms can cause overload in hereditary hemochromatosis 
(commonly associated with HFE, but also with HFE2 (also 
called HJV), HAMP, TFR2 and SLC40A1) or deficiency in iron- 
refractory iron-deficiency anemia (associated with TMPRSS6). 
Although most attention has been paid to variants with major 
effects leading to inherited disease, variation in iron status 
within the general population1,2 is important in relation to risk 
of iron-deficiency anemia, oxidative stress, liver disease and 
metabolic syndrome.
Investigation of iron status in humans can be based on quantitative 
tests including those for serum iron, serum transferrin, transferrin 
saturation with iron, and serum ferritin. We aimed to identify poly-
morphisms causing variation in iron status in the general popula-
tion using genome-wide association methods in 2,516 adolescent 
and 2,302 adult individuals from 2,277 Australian twin families 
(Supplementary Table 1). The genotyping was performed using 
Human610-Quadv1 chips (~582,000 SNPs) and HumanCNV370-
Quadv3 chips (~351,000 SNPs) (Supplementary Methods). We 
 replicated previously reported associations of serum SNPs in TF 
(rs3811647) with serum transferrin and in HFE (rs1800562) with 
serum iron, transferrin and transferrin saturation2 in both the ado-
lescent and adult samples (Table 1, Supplementary Figs. 1 and 2).
We identified significant associations between SNPs in TMPRSS6 
and serum iron (adolescents P = 1.6 × 10−11, adults P = 9.9 × 10−11) 
and transferrin saturation (adolescents P = 9.7 × 10−13, adults 
P = 1.8 × 10−11) (Table 1). The strongest TMPRSS6 association 
was with rs855791, a nonsynonymous coding SNP (resulting in an 
A736V substitution) in exon 17 (Fig. 1). The effects of rs855791 
on serum iron and transferrin saturation were additive, with each 
T allele decreasing serum iron and transferrin saturation by 0.18 
and 0.20 s.d., respectively, of the values associated with the mean 
phenotypes. The SNP explains 2.2% and 2.5% of the variation in 
the means of serum iron and transferrin saturation, respectively, 
in the adolescent cohort and 1.9% and 2.0% in the adult cohort.
Because of the involvement of TMPRSS6 mutations in iron-refractory 
iron-deficiency anemia3 and because low values for blood hemoglobin 
(Hb) and erythrocyte mean cell volume (MCV) occur in iron-defi-
ciency states, we next checked for associations with Hb or MCV. We 
found strong associations of rs855791 to Hb (P = 2.3 × 10−6) and MCV 
(P = 1.3 × 10−5) in the adolescents. The T allele of rs855791 decreased 
mean Hb and MCV by 0.15 and 0.14 s.d., respectively. These cor-
respond to 1.1% and 0.9% of the total variance in mean Hb and 
MCV. We replicated these associations in an independent adult Dutch 
cohort4 consisting of 3,470 unrelated individuals (P = 7.7 × 10−3 and 
1.8 × 10−6 for Hb and MCV, respectively) (Table 1).
Genotypic means for each of the marker phenotypes for the most 
significant SNPs in TF, HFE and TMPRSS6, by sex and study cohort, 
are presented in Supplementary Figure 3a,b. The direction of the allelic 
effects was consistent with expectation, in that the alleles or genotypes 
causing low iron or transferrin saturation were the same in the adults 
and adolescents and were also those associated with lower Hb and MCV. 
The estimated effect sizes, stratified by gender after correcting for the 
effect of age, are presented in Supplementary Table 2. Except for the 
effect of rs1800562 on Hb in the adult cohort, there appear to be no 
significant differences between the estimates for males and females.
To assess whether the effects of rs855791 on Hb and MCV are 
explained by effects on iron status, or whether there may be direct 
effects of HFE or TMPRSS6 variants on erythropoiesis, we repeated 
the SNP association analysis for Hb and MCV in the Australian adoles-
cents using the residuals after adjustment for the effect of transferrin 
saturation (chosen because this measure shows the strongest associa-
tion with rs855791). This first required assessment of the relationships 
between transferrin saturation, Hb and MCV (Supplementary Fig. 4); 
these relationships were essentially linear across the range found in 
this population sample. Results showed that linear adjustment for 
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transferrin saturation reduced but did not eliminate the effects of 
rs855791 in TMPRSS6 on Hb (from R2 = 1.2%, P = 1.4 × 10−6, to 
R2 = 0.5%, P = 0.003), and MCV (from R2 = 0.8%, P = 6.9 × 10−5, 
to R2 = 0.4%, P = 0.008). Similar adjustment essentially eliminated 
the effects of rs1800562 in HFE (for Hb, from 
R2 = 0.8%, P = 1.1 × 10−4, to R2 = 0.2%, 
P = 0.09; for MCV, from R2 = 0.4%, P = 0.007, 
to R2 < 0.1%, P = 0.40). The residual allelic 
association with rs855791, together with the 
strong overall association between transferrin 
saturation and Hb or MCV (Supplementary 
Table 3 and Supplementary Fig. 4), suggest 
that the effects of this TMPRSS6 polymor-
phism on Hb and MCV may not be solely due 
to the availability of transferrin-bound iron 
being rate-limiting for erythropoiesis.
We have shown genome-wide significant 
association of a common SNP in TMPRSS6 
with serum iron, transferrin saturation and 
MCV, and suggestive association with Hb, 
extending previous data2 implicating TMPRSS6 in variation in serum 
iron and transferrin saturation in the general population. Data from 
other sources3,5–7 shows that knockout (in mice) or mutations with 
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figure 1 Detailed results of the associations 
between SNPs within TMPRSS6 and transferrin 
saturation in the adolescent cohort. (a) The 
genomic location of TMPRSS6 at 22q12–q13 on 
chromosome 22. (b) –log10(P) of the association 
tests between SNPs and transferrin saturation, 
where red dots indicate genome-wide significant 
SNPs. rs2160906 has a significant cis-acting 
effect on TMPRSS6 expression (P = 8.4 × 
10−8)10. (c) Linkage disequilibrium (LD)  
(r2) between rs855791 and all other HapMap 
SNPs within TMPRSS6. (d) HapMap-LD plot (r2) 
between genotyped SNPs within TMPRSS6.
table 1 additive effects (in s.d. units) of the three snPs in TMPRSS6, HFE and TF on iron status
Adolescent Adult Combined
Trait N Beta s.e. R2 (%) P N Beta s.e. R2 (%) P Beta s.e. P
rs855791 (TMPRSS6)
Iron 2,505 −0.183 0.027 2.2 1.6 × 10−11 2,298 −0.191 0.030 1.9 9.9 × 10−11 −0.187 0.020 1.5 × 10−20
Transferrin 2,513 0.078 0.029 0.4 7.1 × 10−3 2,299 0.069 0.031 0.2 0.023 0.074 0.021 4.9 × 10−4
Saturation 2,503 −0.196 0.027 2.5 9.7 × 10−13 2,294 −0.198 0.029 2.0 1.8 × 10−11 −0.197 0.020 2.2 × 10−23
Log10(ferritin) 2,512 −0.092 0.028 0.5 8.8 × 10−4 2,301 −0.040 0.030 0.1 0.17 −0.068 0.021 9.3 × 10−4
Hb 2,468 −0.151 0.032 1.1 2.3 × 10−6 3,188 −0.067 0.025 0.2 7.7 × 10−3 −0.099 0.020 5.3 × 10−7
MCV 2,467 −0.139 0.032 0.9 1.3 × 10−5 3,181 −0.120 0.025 0.7 1.8 × 10−6 −0.127 0.020 1.1 × 10−10
rs1800562 (HFE)
Iron 2,502 0.343 0.052 2.2 4.7 × 10−11 2,299 0.315 0.053 1.5 2.5 × 10−9 0.329 0.037 8.2 × 10−19
Transferrin 2,510 −0.602 0.056 6.0 4.3 × 10−27 2,300 −0.605 0.055 5.4 2.9 × 10−28 −0.604 0.039 2.2 × 10−53
Saturation 2,500 0.598 0.053 6.6 2.3 × 10−29 2,295 0.523 0.054 4.2 3.0 × 10−22 0.561 0.038 8.5 × 10−50
Log10(ferritin) 2,509 0.168 0.053 0.5 1.6 × 10−3 2,302 0.103 0.054 0.2 0.06 0.136 0.038 3.4 × 10−4
Hb 2,465 0.236 0.061 0.8 1.2 × 10−4 3,451 0.169 0.051 0.3 9.0 × 10−4 0.197 0.039 5.1 × 10−7
MCV 2,464 0.148 0.061 0.3 0.015 3,442 0.273 0.051 0.8 7.7 × 10−8 0.222 0.039 1.5 × 10−8
rs3811647 (TF)
Iron 2,505 0.073 0.029 0.3 0.012 2,299 0.042 0.032 0.1 0.18 0.059 0.022 0.006
Transferrin 2,513 0.460 0.031 11.2 4.4 × 10−50 2,300 0.371 0.032 6.1 2.1 × 10−30 0.417 0.022 2.1 × 10−78
Saturation 2,503 −0.089 0.029 0.5 2.4 × 10−3 2,295 −0.093 0.031 0.4 3.1 × 10−3 −0.091 0.021 1.8 × 10−5
Log10(ferritin) 2,512 −0.053 0.029 0.2 0.07 2,302 −0.030 0.032 0.1 0.35 −0.044 0.022 0.04
Hb 2,468 −0.019 0.034 0.02 0.58 3,470 0.032 0.026 0.04 0.21 0.013 0.021 0.52
MCV 2,467 −0.041 0.034 0.1 0.23 3,461 −0.042 0.026 0.1 0.10 −0.042 0.021 0.04
Iron status parameters tested were serum iron, serum transferrin, transferrin saturation, serum ferritin and blood hemoglobin (Hb) levels and erythrocyte mean cell volume (MCV). 
The results are from the Australian cohorts, except for Hb and MCV in adults, which are from the Dutch cohort. The results in the adolescent cohort are from the mean of measure-
ments from up to four visits. The rs855791 variant was not genotyped in the Dutch panel and so was imputed using PLINK11 as described previously12. Genotypes were imputed 
with high confidence (information score of 0.97) in 92% of individuals. Minor allele frequencies (MAFs) for rs855791 (T), rs1800562 (A) and rs3811647 (A) in the adolescent 
cohort are 0.42, 0.08 and 0.33, respectively. R2 is the proportion of the phenotypic variance explained by each SNP. After correction for multiple testing, there is no significant 
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of function in this gene produces iron deficiency and anemia, prob-
ably through a combination of protease action on hemojuvelin6 and 
regulation of the expression of hepcidin8. We have now found signifi-
cant and consistent effects of a TMPRSS6 variant on both iron status 
(serum iron and transferrin saturation) and erythropoiesis (Hb and 
MCV) in adolescents and adults from the general population. The 
effects of this nonsynonymous coding variant on both Hb and MCV 
raise important questions about the relationship between iron status 
and normal Hb synthesis. One implication is that transferrin satura-
tion may be involved in the control of erythropoiesis and that alleles 
which increase it allow an increase in Hb and MCV even in people 
who show no evidence of iron deficiency.
There are now confirmed effects on iron markers for three genes, 
each previously known from human case studies or mouse experi-
ments to affect iron homeostasis. TF mainly affects the concentration 
of its protein product transferrin, and this may in turn affect the con-
centration of diferric transferrin, which regulates hepcidin expression 
in the liver by interacting with the HFE and TFR2 gene products9. HFE 
likewise regulates hepcidin, and naturally occurring or experimentally 
induced mutations in this gene lead to iron overload. In our study, the 
associations of HFE to serum iron, serum transferrin and transferrin 
saturation, but not to serum ferritin, met genome-wide significance 
in these cohorts. With the sample size of the cohorts included in this 
study, we do not have power to detect any ferritin-associated SNPs at 
genome-wide significance levels. Note that rs855791 and rs1800562 
were associated with serum ferritin, with combined P values around 
10−4 (Table 1).
Loss-of-function mutations affecting the protease domain of the 
TMPRSS6 gene product, matriptase-2 (also called transmembrane 
protease, serine 6), lead to increased hepcidin expression and iron 
deficiency5–7. The variant that has the largest effect in this study pro-
duces an amino acid change, from alanine to valine at amino acid 
736. This, too, is in the protease domain, and we speculate that it may 
lead to changes in protease activity. Other variants of TMPRSS6 may 
also affect iron status. A report on gene expression in human liver10 
found a cis-acting effect of rs2160906 (P = 8.4 × 10−8, HapMap CEU 
r2 with rs855791 = 0.06) at 35.82 Mb on TMPRSS6 expression, and 
we found strong supportive evidence (combined P = 9.8 × 10−8 with 
transferrin saturation) for an effect of this polymorphism on iron 
status (Fig. 1).
Heritability estimates1 suggest that there must be other genetic 
 contributions to variation in these traits, but their identification will 
require larger studies or meta-analysis of multiple studies. Polygenic effects 
on iron status may have clinical importance for iron overload states, both 
primary (as risk modifiers in HFE C282Y homozygotes) and secondary 
to liver disease or metabolic syndrome, and case-control studies on the 
effects of TMPRSS6 variation in these conditions are needed.
Note: Supplementary information is available on the Nature Genetics website.
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